Positive Phase II data for Teva/CureTech's DLBCL antibody treatment
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries and CureTech have reported positive top-line results for their investigational anti-PD-1 monoclonal antibody, CT-011, from a Phase II trial in patients with diffuse large B cell lymphoma (DLBCL).